Cargando…

Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy

Background and Objectives: A prognosis for kids with pediatric dilated cardiomyopathy (PDCM) is urgently needed to identify high-risk patients. This study aimed to determine the association of levels and soluble suppression of tumorigenicity 2 (sST2) and medical therapy of β-blocker inhibitors with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Meng, Wang, Xiaofang, Liang, Yongmei, Yang, Yifei, Gu, Yan, Wang, Zhiyuan, Lv, Zhenyu, Jin, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606944/
https://www.ncbi.nlm.nih.gov/pubmed/36295500
http://dx.doi.org/10.3390/medicina58101339
_version_ 1784818416835624960
author Jiao, Meng
Wang, Xiaofang
Liang, Yongmei
Yang, Yifei
Gu, Yan
Wang, Zhiyuan
Lv, Zhenyu
Jin, Mei
author_facet Jiao, Meng
Wang, Xiaofang
Liang, Yongmei
Yang, Yifei
Gu, Yan
Wang, Zhiyuan
Lv, Zhenyu
Jin, Mei
author_sort Jiao, Meng
collection PubMed
description Background and Objectives: A prognosis for kids with pediatric dilated cardiomyopathy (PDCM) is urgently needed to identify high-risk patients. This study aimed to determine the association of levels and soluble suppression of tumorigenicity 2 (sST2) and medical therapy of β-blocker inhibitors with the risk of adverse events in PDCM. Materials and Methods: A total of 124 patients with PDCM were enrolled after admission from 2 centers in China and followed up for adverse events (death, cardiac transplantation, and heart-failure-related rehospitalization). Based on a median sST2 level and the usage of β-blocker inhibitors, patients were divided into four groups. The Cox proportional hazard model was used to assess the risk of incident adverse events. Results: The median level of sST2 was 23.77 ng/mL, and 53 (42.7%) patients received β-blocker treatment. Over a median follow-up of 678 days, 37 (29.8%) adverse events occurred. Compared with patients with sST2 < median and without β-blocker, patients with sST2 ≥ median and without β-blocker (HR: 7.01; 95% CI: 1.21–40.45), followed by those with sST2 ≥ median and use of β-blocker had the highest risk of adverse events (hazard ratio (HR): 5.51; 95% confidence interval (CI): 1.17–25.84). However, a significant association was not observed in patients with sST2 < median and use of β-blocker. These associations were consistent across different subgroups. Conclusions: A higher level of sST2 was associated with a higher risk of adverse events in patients with PDCM, and β-blocker treatment for children with high levels of sST2 can effectively avoid adverse events.
format Online
Article
Text
id pubmed-9606944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96069442022-10-28 Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy Jiao, Meng Wang, Xiaofang Liang, Yongmei Yang, Yifei Gu, Yan Wang, Zhiyuan Lv, Zhenyu Jin, Mei Medicina (Kaunas) Article Background and Objectives: A prognosis for kids with pediatric dilated cardiomyopathy (PDCM) is urgently needed to identify high-risk patients. This study aimed to determine the association of levels and soluble suppression of tumorigenicity 2 (sST2) and medical therapy of β-blocker inhibitors with the risk of adverse events in PDCM. Materials and Methods: A total of 124 patients with PDCM were enrolled after admission from 2 centers in China and followed up for adverse events (death, cardiac transplantation, and heart-failure-related rehospitalization). Based on a median sST2 level and the usage of β-blocker inhibitors, patients were divided into four groups. The Cox proportional hazard model was used to assess the risk of incident adverse events. Results: The median level of sST2 was 23.77 ng/mL, and 53 (42.7%) patients received β-blocker treatment. Over a median follow-up of 678 days, 37 (29.8%) adverse events occurred. Compared with patients with sST2 < median and without β-blocker, patients with sST2 ≥ median and without β-blocker (HR: 7.01; 95% CI: 1.21–40.45), followed by those with sST2 ≥ median and use of β-blocker had the highest risk of adverse events (hazard ratio (HR): 5.51; 95% confidence interval (CI): 1.17–25.84). However, a significant association was not observed in patients with sST2 < median and use of β-blocker. These associations were consistent across different subgroups. Conclusions: A higher level of sST2 was associated with a higher risk of adverse events in patients with PDCM, and β-blocker treatment for children with high levels of sST2 can effectively avoid adverse events. MDPI 2022-09-23 /pmc/articles/PMC9606944/ /pubmed/36295500 http://dx.doi.org/10.3390/medicina58101339 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jiao, Meng
Wang, Xiaofang
Liang, Yongmei
Yang, Yifei
Gu, Yan
Wang, Zhiyuan
Lv, Zhenyu
Jin, Mei
Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy
title Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy
title_full Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy
title_fullStr Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy
title_full_unstemmed Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy
title_short Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy
title_sort effect of β-blocker therapy on the level of soluble st2 protein in pediatric dilated cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606944/
https://www.ncbi.nlm.nih.gov/pubmed/36295500
http://dx.doi.org/10.3390/medicina58101339
work_keys_str_mv AT jiaomeng effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy
AT wangxiaofang effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy
AT liangyongmei effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy
AT yangyifei effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy
AT guyan effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy
AT wangzhiyuan effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy
AT lvzhenyu effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy
AT jinmei effectofbblockertherapyonthelevelofsolublest2proteininpediatricdilatedcardiomyopathy